Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma

Aim Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability. Methods Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied. Results The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012). Conclusion This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.1002/bcp.70918
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma

Aurélie Brice, Étienne Chatelut, Loı̈c Mourey, Fabienne Thomas et al.
British Journal of Clinical Pharmacology
Pharmacogenetics and Drug Metabolism
article

Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma

Aurélie Brice, Étienne Chatelut, Loı̈c Mourey, Fabienne Thomas, Florent Puisset, Thierry Lafont, Bastien Cabarrou, Félicien Le Louedec, Helen J. Boyle, Diégo Tosi, Ben Allal, Deniz Ozdin, Frédéric Thuillier, Maud Maillard, Mélanie White‐Koning, Gwénaëlle Gravis, Guilhem Roubaud, Mathieu Landry, Matthieu Gracia, Christelle Moreau, Anne Pradines
article en

Abstract

Aim Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability. Methods Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied. Results The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012). Conclusion This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.

British Journal of Clinical Pharmacology
Centre National de la Recherche Scientifique (FR), Inserm (FR), Aix-Marseille Université (FR), Centre de Recherches en Cancérologie de Toulouse (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre Léon Bérard (FR), Centre Hospitalier Universitaire de Limoges (FR), Institut Claudius Regaud (FR), Institut Bergonié (FR), Centre de Recherche en Cancérologie de Marseille (FR), Institut Paoli-Calmettes (FR), Institut Regional du Cancer de Montpellier (FR), Université de Montréal (CA)
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon